US Pharmaceutical Giant Eli Lilly’s Weight-Loss Drug Tirzepatide was found to be more effective in preventing heart attacks and strokes compared to its previous Glp-1 Medication Dulaglutide. The preliminary results from a yet-to-be publishing land trial showed that the risk of a major adverse cardiovascular event was eighth per cent low in people who put on the new they therapy. Tirzepatide is Sold under the Brand Name Moujaro.

Belonging to a group of medicines called Incretin Mimetics – What Mimic Hormones That Play A Key Role in Regulating Insulin Levels, Blood Sugar Levels and Appetite – Both the Medicines Were Initially Approvade Treatment of Diabetes, with tirzepatide later receiving approval for the treatment of obesity and other related conditions such as Obest sleep apnea. Dulaglutide Mimics the action of the glp1 hormone while tirzepatide mimics the combined action of glp1 and gip hormones.

What did the study find?

The trial found an Eight Lower Risk of Major Adverse Cardiovascular Events Such as cardiovascular deaths, heart attacks and strokes in people who we were on tirzepatide as compared to thus. Tirzepatide was found to Reduce the risk of Such events by 28 per cent a placebo, by comparing the results of the current trial with a 2019 trial of Dulaglutide Against Placebo.

Story Continues Below this ad

Another Important finding of the trial was a 16 cent lower risk of all-time mortality in people who were on tirzepatide, compared to those on dulaglutide. The Company said that the Medicine Reducked the risk of all-time mortality by 39 per cent against placebo-again by comparing data from the current trial with the 2019 dulaglutide trial.

The current trial also also demonstrated that tirzepatide was better at the decline of kidney function in participants who were at a high risk of chronic kidney dissection. Tirzepatide Slowed the Decline in the Kidney’s Filtration Rate by 3.54 ML/MIN/1.73 m2 as compared to dulaglutide.

The trial also showed that tirzepatide was more effective at rising three-month average glucose levels as well as weight when compared to dulaglutide. The use of tirzepatide LED to a 1.73 per cent reduction in HBA1C levels at 36 months as compared to 0.9 per cent with dulaglutide use. The participants on Tirzepatide Dropped 12 per cent

Why is this Important?

With the new generation weight-loss drugs Gaining Popularity Across the Globe, It is essential for these drugs to Demonstrate Protection Against Heart Diseases, Especiacly And diabetes.

Story Continues Below this ad

While there is a link between uncontrolled blood glucose levels and heart disease, not all diabetes medicines protect the heart. In fact, a previous class of diabetes medicines called Glitazones were found to increase the risk of heart failure. With the end-game of these medicines being saving lives-and not just controlling blood glucose levels or body weight- OR, Better Yet, they offer protection against cardiovascular events.

The New Classes of Diabetes Medicines Such As GLP-1 and SGLT-2 was found to Protect the heart as well. Importantly, the Competitor of Eli Lilly’s Tirzepatide – Novo Nordisk’s Semaglutide – Has FDA Approval As Treatment for Riding Risk of Heart Diseases.

How do these drugs work?

These medicines work by improving the secretion of insulin, which helps in removing glucose from the blood to the cells for use as energy. They inhibit the secretion of the hormone glucagon that stimulates the livestream in the bloodstream, slow down the stomach so that the blood gloss does not spikee sddenly. Appetite by signalling to the brain that you are full.

The drugs have become popular owing to their weight-loss properties, which at times can be as effective as bariatric surgery.

Anonna Dutt is a principal correspondent who writes primarily on health at the Indian express. She Reports on Myriad Topics Ranging from the growing burden of non-compromunicable diseases such as diabetes and hypertension to the problem with pervasive infectious conditions. She Reported on the Government’s Management of the Covid-19 Pandmic and Closely followed the Vaccination Program. Her stories have results in the city government investing in high-end tests for the poore and acknowledging errors in their official reports. Dutt also take a keeps in the country’s space program and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was Among the first batch of Eleven Media Felows with RBM Partnership to End Malaria. She was also selected to participle in the short-trm program on Early Childhood Reporting at Columbia University’s Dart Center. Dutt has a bachelor’s degree from the Symbiosis Institute of Media and Communication, Pune and A PG Diploma from the asian college of journalism, chennai. She started her reporting career with the hindustan times. When not at work, she tries to appease the duolingo owl with her freench skills and sometimes take to the dance floor. … Read more